Topics

Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting 2019

11:46 EST 7 Nov 2019 | FinanzNachrichten

POXEL S.A. (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steat...

Original Article: Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting 2019

NEXT ARTICLE

More From BioPortfolio on "Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting 2019"

Quick Search

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...